Cancer Medicine (Jul 2024)

Clinical features, MRI, molecular alternations, and prognosis of astrocytoma based on WHO 2021 classification of central nervous system tumors: A single‐center retrospective study

  • Yuekun Wang,
  • Hao Xing,
  • Xiaopeng Guo,
  • Wenlin Chen,
  • Yaning Wang,
  • Tingyu Liang,
  • Hai Wang,
  • Yilin Li,
  • Shanmu Jin,
  • Yixin Shi,
  • Delin Liu,
  • Tianrui Yang,
  • Yu Xia,
  • Junlin Li,
  • Jiaming Wu,
  • Qianshu Liu,
  • Tian Qu,
  • Siying Guo,
  • Huanzhang Li,
  • Kun Zhang,
  • Yu Wang,
  • Wenbin Ma

DOI
https://doi.org/10.1002/cam4.7369
Journal volume & issue
Vol. 13, no. 13
pp. n/a – n/a

Abstract

Read online

Abstract Background The diagnosis of glioma has advanced since the release of the WHO 2021 classification with more molecular alterations involved in the integrated diagnostic pathways. Our study aimed to present our experience with the clinical features and management of astrocytoma, IDH mutant based on the latest WHO classification. Methods Patients diagnosed with astrocytoma, IDH‐mutant based on the WHO 5th edition classification of CNS tumors at our center from January 2009 to January 2022 were included. Patients were divided into WHO 2–3 grade group and WHO 4 grade group. Integrate diagnoses were retrospectively confirmed according to WHO 2016 and 2021 classification. Clinical and MRI characteristics were reviewed, and survival analysis was performed. Results A total of 60 patients were enrolled. 21.67% (13/60) of all patients changed tumor grade from WHO 4th edition classification to WHO 5th edition. Of these, 21.43% (6/28) of grade II astrocytoma and 58.33% (7/12) of grade III astrocytoma according to WHO 4th edition classification changed to grade 4 according to WHO 5th edition classification. Sex (p = 0.042), recurrent glioma (p = 0.006), and Ki‐67 index (p < 0.001) of pathological examination were statistically different in the WHO grade 2–3 group (n = 27) and WHO grade 4 group (n = 33). CDK6 (p = 0.004), FGFR2 (p = 0.003), and MYC (p = 0.004) alterations showed an enrichment in the WHO grade 4 group. Patients with higher grade showed shorter mOS (mOS = 75.9 m, 53.6 m, 26.4 m for grade 2, 3, and 4, respectively, p = 0.01). Conclusions Patients diagnosed as WHO grade 4 according to the 5th edition WHO classification based on molecular alterations are more likely to have poorer prognosis. Therefore, treatment should be tailored to their individual needs. Further research is needed for the management of IDH‐mutant astrocytoma is needed in the future.

Keywords